231 related articles for article (PubMed ID: 38630822)
1. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.
Xu AM; Haro M; Walts AE; Hu Y; John J; Karlan BY; Merchant A; Orsulic S
Sci Adv; 2024 Apr; 10(16):eadk8805. PubMed ID: 38630822
[TBL] [Abstract][Full Text] [Related]
2. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
3. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma.
Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X
Front Immunol; 2022; 13():940801. PubMed ID: 36119108
[TBL] [Abstract][Full Text] [Related]
5. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
6. Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer.
Loret N; Vandamme N; De Coninck J; Taminau J; De Clercq K; Blancke G; Jonckheere S; Goossens S; Lemeire K; De Prijck S; Verstaen K; Seurinck R; Van Dorpe J; Weyers S; Denys H; Van de Vijver K; Lambrecht BN; Tummers P; Saeys Y; Berx G
Mol Cancer Res; 2022 Oct; 20(10):1532-1547. PubMed ID: 35749080
[TBL] [Abstract][Full Text] [Related]
7. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer.
Lu H; Lou H; Wengert G; Paudel R; Patel N; Desai S; Crum B; Linton-Reid K; Chen M; Li D; Ip J; Mauri F; Pinato DJ; Rockall A; Copley SJ; Ghaem-Maghami S; Aboagye EO
Cell Rep Med; 2023 Jul; 4(7):101092. PubMed ID: 37348499
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
9. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K; Xie X; Zou LH; Guo SQ
Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
[TBL] [Abstract][Full Text] [Related]
10. Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
James NE; Woodman M; De La Cruz P; Eurich K; Ozsoy MA; Schorl C; Hanley LC; Ribeiro JR
Front Immunol; 2022; 13():965331. PubMed ID: 36131935
[TBL] [Abstract][Full Text] [Related]
11. Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer.
Yang H; Yu M; Zhong S; You Y; Feng F
J Ovarian Res; 2022 Jan; 15(1):18. PubMed ID: 35093146
[TBL] [Abstract][Full Text] [Related]
12. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
13. Altered tumor signature and T-cell profile after chemotherapy reveal new therapeutic opportunities in high-grade serous ovarian carcinoma.
Kang H; Hwang S; Kang H; Jo A; Lee JM; Choi JK; An HJ; Lee HO
Cancer Sci; 2024 Mar; 115(3):989-1000. PubMed ID: 38226451
[TBL] [Abstract][Full Text] [Related]
14. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.
Wilczyński J; Paradowska E; Wilczyńska J; Wilczyński M
Curr Oncol; 2023 Dec; 31(1):229-249. PubMed ID: 38248100
[TBL] [Abstract][Full Text] [Related]
16. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma.
Sanders BE; Yamamoto TM; McMellen A; Woodruff ER; Berning A; Post MD; Bitler BG
Mol Cancer Ther; 2022 Aug; 21(8):1285-1295. PubMed ID: 35587258
[TBL] [Abstract][Full Text] [Related]
17. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
18. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
Yeung TL; Sheng J; Leung CS; Li F; Kim J; Ho SY; Matzuk MM; Lu KH; Wong STC; Mok SC
J Natl Cancer Inst; 2019 Mar; 111(3):272-282. PubMed ID: 29860390
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.
Brown Y; Hua S; Tanwar PS
Matrix Biol; 2023 Apr; 118():16-46. PubMed ID: 36781087
[TBL] [Abstract][Full Text] [Related]
20. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]